# Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

> **NCT02043288** · PHASE3 · COMPLETED · sponsor: **Orient Europharma Co., Ltd.** · enrollment: 310 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** NC-6004
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02043288
- **Lead sponsor:** Orient Europharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2020-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02043288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02043288, "Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02043288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*